Australia markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
7.89+0.37 (+4.92%)
At close: 04:00PM EDT
7.79 -0.10 (-1.27%)
After hours: 07:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 9.22B
Enterprise value 30.35B
Trailing P/E 872.00
Forward P/E 3.16
PEG ratio (5-yr expected) 0.63
Price/sales (ttm)0.56
Price/book (mrq)0.93
Enterprise value/revenue 1.95
Enterprise value/EBITDA 18.08

Trading information

Stock price history

Beta (5Y monthly) 1.18
52-week change 3-17.90%
S&P500 52-week change 3-11.93%
52-week high 310.50
52-week low 37.23
50-day moving average 38.35
200-day moving average 38.72

Share statistics

Avg vol (3-month) 310.01M
Avg vol (10-day) 314.75M
Shares outstanding 51.11B
Implied shares outstanding 6N/A
Float 81.1B
% held by insiders 11.50%
% held by institutions 146.07%
Shares short (14 June 2022) 419.38M
Short ratio (14 June 2022) 42.21
Short % of float (14 June 2022) 4N/A
Short % of shares outstanding (14 June 2022) 41.75%
Shares short (prior month 12 May 2022) 420.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 311 Dec 2017
Ex-dividend date 426 Nov 2017
Last split factor 22:1
Last split date 330 June 2004

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -3.95%
Operating margin (ttm)19.25%

Management effectiveness

Return on assets (ttm)3.90%
Return on equity (ttm)-5.46%

Income statement

Revenue (ttm)15.56B
Revenue per share (ttm)14.09
Quarterly revenue growth (yoy)-8.10%
Gross profit (ttm)7.59B
Net income avi to common (ttm)-615M
Diluted EPS (ttm)-0.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.18B
Total cash per share (mrq)1.96
Total debt (mrq)23.31B
Total debt/equity (mrq)227.19
Current ratio (mrq)1.07
Book value per share (mrq)8.41

Cash flow statement

Operating cash flow (ttm)1.15B
Levered free cash flow (ttm)2.66B